Display options
Cite
Sen V, Aydogdu O, Bozkurt IH, et al. The use of prophylactic single-dose fosfomycin in patients who undergo transrectal ultrasound-guided prostate biopsy: A prospective, randomized, and controlled clinical study. Can Urol Assoc J. 2015;9(11):E863-7doi: 10.5489/cuaj.3068.
Sen, V., Aydogdu, O., Bozkurt, I. H., Yonguc, T., Sen, P., Polat, S., Degirmenci, T., & Bolat, D. (2015). The use of prophylactic single-dose fosfomycin in patients who undergo transrectal ultrasound-guided prostate biopsy: A prospective, randomized, and controlled clinical study. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 9(11), E863-7. https://doi.org/10.5489/cuaj.3068
Sen, Volkan, et al. "The use of prophylactic single-dose fosfomycin in patients who undergo transrectal ultrasound-guided prostate biopsy: A prospective, randomized, and controlled clinical study." Canadian Urological Association journal = Journal de l'Association des urologues du Canada vol. 9,11 (2015): E863-7. doi: https://doi.org/10.5489/cuaj.3068
Sen V, Aydogdu O, Bozkurt IH, Yonguc T, Sen P, Polat S, Degirmenci T, Bolat D. The use of prophylactic single-dose fosfomycin in patients who undergo transrectal ultrasound-guided prostate biopsy: A prospective, randomized, and controlled clinical study. Can Urol Assoc J. 2015 Nov-Dec;9(11):E863-7. doi: 10.5489/cuaj.3068. Epub 2015 Dec 14. PMID: 26788236; PMCID: PMC4707906.
Copy Download .nbib Format: NLM
Share it on

Can Urol Assoc J. 2015 Nov-Dec;9(11):E863-7. doi: 10.5489/cuaj.3068. Epub 2015 Dec 14.

The use of prophylactic single-dose fosfomycin in patients who undergo transrectal ultrasound-guided prostate biopsy: A prospective, randomized, and controlled clinical study.

Canadian Urological Association journal = Journal de l'Association des urologues du Canada

Volkan Sen, Ozgu Aydogdu, Ibrahim Halil Bozkurt, Tarik Yonguc, Pinar Sen, Salih Polat, Tansu Degirmenci, Deniz Bolat

Affiliations

  1. Izmir Bozyaka Training and Research Hospital Department of Urology, Izmir, Turkey;
  2. Izmir Katip Celebi University Ataturk Training and Research Hospital Department of Infectious Diseases and Clinical Microbiology, Izmir, Turkey.

PMID: 26788236 PMCID: PMC4707906 DOI: 10.5489/cuaj.3068

Abstract

INTRODUCTION: We aimed to demonstrate the efficacy, safety, and convenient use of fosfomycin trometamol in the preoperative antibiotic prophylaxis (PAP) of transrectal ultrasound-guided biopsy of the prostate (TRUSBP) in this prospective, randomized study.

METHODS: Between May 2014 and May 2015, a total of 300 patients who underwent TRUSBP were examined prospectively. Patients were randomized into two groups: group 1 consisted of 150 patients who were administered a single dose of 3 g oral fosfomycin as a PAP the night before the procedure; group 2 consisted of 150 patients who were administered 500 mg oral ciprofloxacin 60 min before the procedure as a PAP. Post-procedural febrile and afebrile infectious complications and pathological characteristics of the two groups were compared prospectively.

RESULTS: The mean age of the patients was 63.5±0.6 years in group 1 and 62.9±0.6 years in group 2. A total of two patients (1.3%) in group 1 and nine patients (6.0%) in group 2 experienced afebrile urinary tract infection (UTI). Afebrile UTI rate was significantly higher in group 2 (1.3% s. 6.0%, p=0,032). Febrile UTI was detected in two patients in group 2 and one patient in group 1. Urine cultures revealed 35.7% fluoroquinolone resistance. As a limitation, although the sample size was appropriate due to the power calculation, we believe that comprehensive studies including larger patient cohorts are needed to support our findings.

CONCLUSIONS: Due to its ease-of-use with only a single dose and lower rates of infectious complications (resistant and febrile UTIs), fosfomycin trometamol is a strong alternative for antibiotic prophylaxis in TRUSBP.

References

  1. Urol Int. 2012;89(4):439-44 - PubMed
  2. Clin Infect Dis. 2011 Mar 1;52(5):e103-20 - PubMed
  3. J Urol. 2011 Apr;185(4):1283-8 - PubMed
  4. Clin Infect Dis. 2003 Dec 15;37(12):1643-8 - PubMed
  5. Int Urol Nephrol. 2012 Aug;44(4):1055-63 - PubMed
  6. Am J Infect Control. 1999 Apr;27(2):97-132; quiz 133-4; discussion 96 - PubMed
  7. J Urol. 2012 Apr;187(4):1275-9 - PubMed
  8. Eur Urol. 2008 Nov;54(5):1164-75 - PubMed
  9. Eur Urol. 2013 Dec;64(6):876-92 - PubMed
  10. Eur Urol. 2012 Sep;62(3):453-9 - PubMed
  11. Br J Urol. 1985 Aug;57(4):478-82 - PubMed
  12. Curr Opin Urol. 2001 Jan;11(1):81-5 - PubMed
  13. Clin Infect Dis. 2014 Feb;58(4):e101-5 - PubMed
  14. Cochrane Database Syst Rev. 2011 May 11;(5):CD006576 - PubMed
  15. Eur Urol. 2013 Mar;63(3):521-7 - PubMed
  16. J Urol. 2010 Feb;183(2):688-92 - PubMed
  17. J Antimicrob Chemother. 2010 Nov;65(11):2459-63 - PubMed
  18. Actas Urol Esp. 2014 Jul-Aug;38(6):391-6 - PubMed
  19. BJU Int. 2010 Nov;106(9):1298-302; discussion 1302 - PubMed
  20. Can J Urol. 2004 Aug;11(4):2352-3 - PubMed
  21. ScientificWorldJournal. 2013 Dec 23;2013:452107 - PubMed
  22. Lancet Infect Dis. 2010 Jan;10(1):43-50 - PubMed
  23. J Urol. 2008 Mar;179(3):952-5; discussion 955 - PubMed
  24. Clin Infect Dis. 2008 Apr 1;46(7):1069-77 - PubMed
  25. J Urol. 2010 Mar;183(3):963-8 - PubMed
  26. Clin Infect Dis. 2013 Jul;57(2):267-74 - PubMed
  27. Science. 1969 Oct 3;166(3901):122-3 - PubMed

Publication Types